Side note:

Percussion music plays.

Alton:

You can’t scale a big mountain if you're institution is small. But a big institution that acts very small to clients can scale large mountains.

Melissa:

We often get asked the question why J.P. Morgan is focused on the innovation economy today. And my answer to that is that this is not a new business for J.P. Morgan.

Alton:

We have 15,000 clients in the commercial bank. We have 4 million start-ups in the business bank.

Melissa:

What we offer to startups is a simplified payments platform to meet all of their basic banking needs. We've tried to make it very simple for them to make payments, get paid, and to help them stay safe from a cybersecurity perspective.

James:

The bankers have not just the ability to advise you on treasury services, or cash management, or traditional banking subjects, but are able to then relate that to a specific subindustry.

Alton:

We target this startup community with very specific products, services, and honestly discussions. If you think about that scale and pace, you’ve gotta start small but you have to get big really quickly.

Holly:

It's incredibly flattering to have such a world-renowned institution behind a young brand and a mission. And J.P. Morgan is the right partner to help us build this brand and take me on this journey.

Melissa:

It's literally impossible to outgrow J.P. Morgan. From, again, you're very basic banking needs to as you grow over time, we can really scale and grow with the company through every stage of their life cycle.

James:

Our bankers live and breathe this. Every time I meet a founder, I'm energized by their vision. They see patterns and connections other people don't see.

Alton:

Although they see the product around the corner, I'm actually helping their company itself look around the corner. So I feel like we're partners.

END

Christine: The industry of healthcare has made huge strides over the years if you look at the innovation that has taken place.

Peter: You're seeing a massively accelerated pace of this technological development.

Lisa: I think that the word disruptive is a word that's synonymous with healthcare today.

Peter: It's a very exciting time, a very dynamic time, but one with a lot of disparate factors that are all at play.

Lisa: At J.P. Morgan we know the industries well, we know the trends, we know what institutional investors are going to be looking for.

Christine: J.P. Morgan has a long history in working with and advising healthcare companies within the life sciences industry.

Sam: These are people working in very complex areas of science, and they're about to make a scientific discovery that's going to impact millions and millions of people for positive reason.

Sam: One of the reasons we started the life sciences practice is we saw a need in the sector, in the community, in the market for this type of advice.

Peter: We focus on the things that we're really good at, so our clients can focus on the things that they're really good at. What they really want is a partner that understands what they do. This is really the only effort that I know of to dedicate a full banking effort around what does the company do? How do I manage my own personal wealth? How do I expand overseas? Start thinking about an exit down the road. All of those different aspects, we can help with.

Christine: Being able to work with a client and their company across their entire lifecycle, from start to finish, is really one of the biggest key strengths that we see for entrepreneurs and for companies.

Lisa: What makes J.P. Morgan different is that we work really collaboratively, and every day it's about building each other up and being a single J.P. Morgan to our clients across the entire bank.

Christine: When a client has that ultimate success, whether it's FDA approval, the sale of their company, or an IPO, being able to share in the success and know that we gave them the sleep at night is one of the greatest points of satisfaction in our role.

Peter: One of the challenges we see in the market right now is entrepreneurs will come to us and say, "I'm not ready for J.P. Morgan yet. We're too small." You might be small in size, which a lot of life sciences companies are, but it doesn't mean you're small in potential. There's many different aspects to the life sciences community where your first reaction is how do I help this company? Being able to help companies along this journey to do something that's truly life changing, I think it's one of the things that drives our people that are focused on this space to go above and beyond.